A carregar...
Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries
BACKGROUND: Two antifibrotic drugs, pirfenidone and nintedanib, are approved by the European Medicines Agency and the US Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis (IPF). In this analysis, treatment patterns of European patients with IPF were investigated to unde...
Na minha lista:
| Publicado no: | BMC Pulm Med |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5602932/ https://ncbi.nlm.nih.gov/pubmed/28915874 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12890-017-0468-5 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|